s
We aim at creating a stable and quality driven research cluster in Biomedicine.

Immunology Biomarkers Research Group (IN1) (WEB)

Main lines of research:

Medical related projects of this group are:
1 .- Obtention of monoclonal antibodies for therapeutic purposes
2 .- The study of immune response to vaccines
3 .- Toxicity of nanoparticles
4 .- Design of biosensors with antibodies.

Description:

The Immunology group headed by Prof. Africa González (Medical specialist in Immunology and Full Professor of Immunology at the University of Vigo) is collaborating with researchers in Vigo Hospital Complex for over 12 years, participating in various joint research projects.

Leads a Shared Unit Sergas-Universidade de Vigo in Immunology with Dr. Gambon, and within medical area,
- has collaborations with Hospital Units such as Preventive Medicine, Internal Medicine, Hematology, Rheumatology and Otolaryngology.
- focuses medical research in immune response and immunotherapy.
- developed also tuberculosis research, obtaining antibodies to leukemia, detection of inflammatory cells in synovial fluid and identification of lymphocyte subpopulations in peripheral lymph nodes of head and neck tumors.
- has supervised many PhD students and supervising PhD theses of physicians of the Internal Medicine Unit.

It takes part in CONSOLIDER INGENIO-2010 national project, in coordination with the group of Prof. Luis Liz (Chemistry-Physics, QF1 group), funded by Ministry of Science and Technology and the FIS (Fondo de Investigación Sanitaria -Health Research Fund-)

It has also been awarded a European project (HINAMOX, coordinator Sergio Moya) under the 7th Framework Program and will be Coordinator of another European Project within SUDOE Call, of a Network of Immunotherapy, which aims to bring together the experiences of different international groups in the field of immunotherapy. This network is inviting physicians to participate with their expertise in monoclonal antibody therapy, cytokines, and dendritic cells.

At the moment, it has four patents, three of them are directly related to the therapeutic field (human monoclonal antibodies directed against tumor and inflammatory human cells) and diagnostics (development of a biosensor for tumor detection).

Recently submitted a business initiative called "NanoImmunotech" which was nominated for Genome-Galicia Spain-BIC IGAPE for the best project, and other awards that reinforce the interest of this spin-off centered on the characterization of nanoparticles and monoclonal antibodies.